Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
100 hedge funds and large institutions have $385M invested in Intra-Cellular Therapies Inc. in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 27 closing their positions.
350% more call options, than puts
Call options by funds: $6.76M | Put options by funds: $1.5M
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
15% less funds holding
Funds holding: 117 → 100 (-17)
19% less capital invested
Capital invested by funds: $476M → $385M (-$91.7M)
59% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$10.7M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$7.59M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.94M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.06M |
| 5 |
Goldman Sachs
New York
|
+$5.19M |
Top Sellers
| 1 |
CCI
Columbus Circle Investors
|
-$6.19M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$6.05M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$5.85M |
| 4 |
Millennium Management
New York
|
-$5.73M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.44M |
ITCI Hedge Fund Activity: Q2 2017 in Review
100 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2017, worth a combined $385M — down 19% from $476M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ITCI and 11 opened new positions — a net loss of 16 holders — while 29 trimmed existing stakes and 35 added.
The largest buyer was Bank of America, adding an estimated $10.7M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $6.19M sold.
- 100 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2017, down from 117 in Q1 2017.
- Funds reported $385M of Intra-Cellular Therapies Inc. stock for Q2 2017, down 19% quarter-over-quarter.
- 11 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2017 and 27 closed out, a net change of -16 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2017 was Bank of America, an estimated $10.7M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2017 was Columbus Circle Investors, an estimated $6.19M sold.
Based on aggregated 13F filings for Q2 2017.